Page 23 - Tech Transfer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dec 28, 2020 8:41am Following a trial error and a data release that only raised more questions, AstraZeneca now has a "winning formula" for its COVID-19 vaccine, CEO Pascal Soriot told the Sunday Times. (AstraZeneca) AstraZeneca's early COVID-19 trial data not only fell short of Pfizer and Moderna's expectation-beating stats, they raised a host of questions thanks to a dosing error in one group of trial patients. But with the U.K. suffering under a new viral strain and a quick vaccine approval expected, CEO Pascal Soriot says AZ has a new "winning formula." In the company's original phase 3...

Dec 23, 2020 9:47am Takeda is selling five cardiovascular and metabolism drugs in the Chinese market to local company Hasten Biopharmaceutic for $322 million. (Takeda) Takeda has already exceeded the product sell-off goal it set alongside its Shire merger, but the Japanese pharma shows no sign of slowing down. After making several geography-specific divestitures in different regions of the world, Takeda has turned to China. The company said Monday it agreed to offload some cardiovascular and metabolic drugs in the Chinese mainland to local firm Hasten Biopharmaceutic for $322 million. The de...

Dec 22, 2020 7:59am The European approval for ViiV Healthcare's HIV treatment Vocabria comes nine months after Health Canada became the first regulator to clear the drug. (artJazz/iStock/Getty Images Plus/Getty Images)(Photo by artJazz/iStock/Getty Images Plus/Getty Images) ViiV Healthcare has won approval for its long-acting injectable HIV treatment Vocabria in Europe. The authorization clears ViiV to sell a drug that could reduce the number of doses patients need to take a year from 365 to six. Combinations of oral antiretrovirals, such as ViiV’s own Combivir and Trizivir, form the backbo...

Dec 22, 2020 3:00am Drug manufacturers are looking for a more local future for production post-COVID-19. (Pixabay)(Monica Alleven/Fierce Wireless) With the COVID-19 pandemic perhaps entering its final phase as the first wave of vaccines approaches the market, one question left unanswered is the future of "onshoring" drug manufacturing—an initiative that reached fever pitch in 2019 as nationwide lockdowns and geopolitical tension cast a spotlight on the global supply chain. In 2019, congressional leaders across the aisle picked up steam on a suite of bills aimed at incentivizing and driving ...

RA Session II, founder, president and CEO of Taysha (Taysha Gene Therapies) Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September. With its lead program now approved for human trials in Canada, the company is sketching out plans for what it hopes will become its prime commercial manufacturing site. Taysha leased a 187,000-square-foot commercial-scale manufacturing facility in Durham, North Carolina, planning to invest $75 million to kit out the facility for preclinical, clinical and comme...